secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2023-05-31T23:59:59+00:00
Accession:  0001935979-23-000037
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven submits NDA for troriluzole in SCA3; updates on Kv7, TYK2/JAK1, and SMA pipeline
--------------------------------------------------------------------------------

- Submitted NDA to FDA for troriluzole in SCA3, an ultra-rare disease affecting ~10,600 people in NA, EU, Japan.
- Phase 1 safety data for BHV-7000 (Kv7.2/3 activator) validates differentiated profile; pivotal studies in focal epilepsy and bipolar disorder planned in 2H2023.
- Initiated Phase 1 study for BHV-8000 (brain-penetrant TYK2/JAK1 inhibitor); Phase 2 in Parkinson's expected next year.
- Global Phase 3 trial of taldefgrobep alfa in SMA enrollment of ~225 patients expected to complete in 2023.
- IND for novel IgG degrader BHV-1300 on track for submission in 2023; multiple new INDs planned within next year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597923000037/0001935979-23-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597923000037/bhvn-20230531.htm
  HTML page:      https://secwatch.observer/filing/0001935979-23-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer